Education
About Us
Working with TipRanks
Follow Us
Daxor Corp (DXR)
NASDAQ:DXR
DXR Stock Chart & Stats
$13.28
-$0.12(-1.54%)
At close: 4:00 PM EST
$13.28
-$0.12(-1.54%)
Day’s Range― - ―
52-Week Range$7.00 - $14.76
Previous CloseN/A
Volume734.00
Average Volume (3M)1.99K
Market Cap
N/A
Enterprise Value$62.74M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$262.93K
Price to Earnings (P/E)34.0
Beta0.58
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding5,827,225
10 Day Avg. Volume865
30 Day Avg. Volume1,994
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)1.04
Price to Sales (P/S)17.48
P/FCF Ratio1.45K
Enterprise Value/Market Cap10.00T>
Enterprise Value/Revenue87.92
Enterprise Value/Gross Profit98.19
Enterprise Value/Ebitda18.78
Forecast
1Y Price Target
$23.00Price Target Upside73.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.8
Revenue Forecast (FY)$50.27M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a sizable equity base provide a material solvency buffer and financial optionality. This reduces refinancing and bankruptcy risk during revenue troughs, enabling the company to fund operations, maintenance, or selective investment without immediate external capital in the next 2–6 months.
Niche Medical SpecialtyA concentrated product focus on blood volume measurement and clinical decision support targets complex, recurring clinical needs. Specialized devices plus disposables and service revenue create higher switching costs and recurring demand from hospitals, supporting durable installed‑base cash flows and clinical adoption over time.
Return To ProfitabilityAchieving positive net income and a healthy reported margin in 2024 demonstrates the business can operate profitably at current scale. Sustained profitability would indicate operating leverage and improve internal funding ability, reducing reliance on external capital if revenue stabilizes over subsequent quarters.
Bears Say
Weak Cash ConversionOperating cash flow was barely positive in 2024 and far below reported earnings, with a very low OCF-to-net-income ratio and prior multi‑year negative cash flow. Poor cash conversion constrains reinvestment, increases financing reliance, and weakens the firm’s ability to withstand revenue volatility over months.
Revenue And Earnings VolatilityHistorical swings in revenue and operating results reduce predictability of future cash flows and make capacity planning and commercial investments risky. Such volatility complicates long‑term contract wins, reimbursement negotiations, and strategic partnerships, impeding steady market expansion over the medium term.
Small Scale And Low LiquidityVery small organizational scale and limited trading liquidity constrain commercial reach, R&D resources, and the pace of hospital penetration. Limited scale increases execution risk, slows durable market share gains, and can raise the effective cost of capital or delay needed investments over a multi‑month horizon.
Daxor News
DXR FAQ
What was Daxor Corp’s price range in the past 12 months?
Daxor Corp lowest stock price was $7.00 and its highest was $14.76 in the past 12 months.
What is Daxor Corp’s market cap?
Currently, no data Available
When is Daxor Corp’s upcoming earnings report date?
Daxor Corp’s upcoming earnings report date is Feb 26, 2026 which is in 10 days.
How were Daxor Corp’s earnings last quarter?
Daxor Corp released its earnings results on Aug 21, 2025. The company reported -$0.074 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.074.
Is Daxor Corp overvalued?
According to Wall Street analysts Daxor Corp’s price is currently Undervalued.
Does Daxor Corp pay dividends?
Daxor Corp pays a Monthly dividend of $0.03 which represents an annual dividend yield of N/A. See more information on Daxor Corp dividends here
What is Daxor Corp’s EPS estimate?
Daxor Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daxor Corp have?
Daxor Corp has 5,827,225 shares outstanding.
What happened to Daxor Corp’s price movement after its last earnings report?
Daxor Corp reported an EPS of -$0.074 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.518%.
Which hedge fund is a major shareholder of Daxor Corp?
Currently, no hedge funds are holding shares in DXR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daxor Corp
Daxor Corporation (DXR) is a medical instrumentation and biotechnology company that specializes in blood volume analysis technology. The company focuses on advancing healthcare by providing innovative diagnostic tools and services that enhance the understanding and treatment of various medical conditions. Daxor's flagship product, the BVA-100, is an FDA-cleared diagnostic device that measures human blood volume, aiding in the precise assessment of fluid management in patients.
DXR Stock 12 Month Forecast
Average Price Target
$23.00
▲(73.19% Upside)
Technical Analysis
Ownership Overview
6.22% Insiders
0.97% Mutual Funds
0.32% Other Institutional Investors
91.52% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---